KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Common Equity (2016 - 2025)

Historic Common Equity for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to $48.7 billion.

  • Astrazeneca's Common Equity rose 1920.19% to $48.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $48.7 billion, marking a year-over-year increase of 1920.19%. This contributed to the annual value of $48.7 billion for FY2025, which is 1920.19% up from last year.
  • Latest data reveals that Astrazeneca reported Common Equity of $48.7 billion as of Q4 2025, which was up 1920.19% from $46.0 billion recorded in Q3 2025.
  • Astrazeneca's Common Equity's 5-year high stood at $48.7 billion during Q4 2025, with a 5-year trough of $14.4 billion in Q1 2021.
  • Its 5-year average for Common Equity is $37.1 billion, with a median of $38.3 billion in 2023.
  • As far as peak fluctuations go, Astrazeneca's Common Equity skyrocketed by 22752.27% in 2021, and later tumbled by 1192.12% in 2022.
  • Astrazeneca's Common Equity (Quarter) stood at $39.3 billion in 2021, then dropped by 5.67% to $37.1 billion in 2022, then increased by 5.69% to $39.2 billion in 2023, then increased by 4.35% to $40.9 billion in 2024, then rose by 19.2% to $48.7 billion in 2025.
  • Its Common Equity stands at $48.7 billion for Q4 2025, versus $46.0 billion for Q3 2025 and $44.8 billion for Q2 2025.